BridgeBio Pharma 1 article

BridgeBio Pharma occupies a defined biopharma niche through genetic disease therapeutics and genetically defined disease drug development, consistent with its role as a genetic-disease biopharmaceutical company. BridgeBio Pharma is also associated with transthyretin stabilization therapy and FGFR3 pathway modulation for skeletal dysplasia; achondroplasia therapeutics supplies another durable point of scientific differentiation. GenoMethods separates the corporate identity of BridgeBio Pharma from its drug-level entities; Canavan disease gene therapy remains useful for company-level matching.